for / peptide sellers

Stripe, PayPal, Square, and Adyen have all categorically rejected MCC 5122. Here's the rail that hasn't.

Peptide sellers occupy the single most-declined MCC in high-risk e-commerce. Every mainstream aggregator refuses onboarding on principle, and the specialist offshore acquirers that will board you charge 6–10% blended cost with 18–24 month rolling reserves. Stablecoin settlement bypasses the classification system entirely.

// approval-rate benchmarklast 30d
industry avg — Peptides & research chems
18%decline rate
transactions killed by risk rules, MCC blocks, and BIN filters
our stack
100%approval rate
not 99.99% — 100% on qualified volume, verifiable in your ledger
Every 18 out of 100 transactions your current processor kills is revenue you already paid to acquire. Our routing + wallet stack clears the full 100 — the ROI conversation stops being about basis points and starts being about the 18% of gross you’re currently leaving on the table. See the commitments we sign to keep it there →
MCC 5122
categorically banned by Stripe, PayPal, Square, Adyen
source ↗
18–25%
typical rolling reserve on offshore peptide MIDs
source ↗
$0.60–$1.50
typical TRC20 network fee per transaction
// where the current model breaks
MCC 5122 categorically banned by every mainstream aggregator

Stripe, PayPal, Square, Adyen, and Braintree list peptides and research chemicals in their prohibited-goods policies. Even domestic high-risk specialists frequently reject peptides after underwriting review.

Offshore acquirers demand 18–25% rolling reserves

The processors who will board a peptide MID typically hold 18–25% of gross volume for 12–24 months. For a $100k/month seller that's $216k–$600k of locked capital sitting with a counterparty with documented exit-scam history.

Sudden termination is the norm, not the exception

Peptide MIDs are among the shortest-lived in high-risk processing. Acquirer-side de-risking waves in 2024 and 2025 wiped out entire portfolios of peptide sellers with 30 days notice — and 90–180 day post-termination fund holds.

// why the cashier works for this vertical
  • Stablecoin rails have no MCC. No mainstream aggregator can 'reject peptides' — the classification doesn't exist on the rail.
  • No rolling reserve. Funds are spendable at on-chain finality (~3 seconds on TRC20).
  • No underwriting file, no 12 months of processing statements, no personal guarantee.
  • Weekly agent settlement supported for domestic USD needs, structured through the same channel.
// objections

Questions operators in this vertical ask.

How do customers pay if they don't own crypto?

The cashier supports Cash App, Zelle, Apple Pay, Venmo, and PayPal as customer-facing rails. Payment proofs are verified automatically via screenshot detection and cross-rail confirmation. Customers pay in the rail they know; the operator settles in stablecoin.

Is this legal for US-based peptide sellers?

Payment rail choice does not change the underlying regulatory status of the product. The cashier is a payment infrastructure — operators are responsible for their own compliance with FDA, DEA, and state-level rules. What the cashier does provide is a legally-recognized settlement rail (GENIUS Act, July 2025) that mainstream card networks refuse to route.

What if a customer files a dispute with their bank?

Disputes on the customer-side rail (Cash App, Zelle, etc.) are handled by that rail — not by you. Once payment is verified and the operator settles in stablecoin, the on-chain transaction is final. You are not exposed to CNP chargeback liability the way you would be on a card MID.

// related verticals
// deeper reading
Full three-way comparison with sources →
// proof
Operator case studies →

$ contact --vertical peptides

If the numbers match your P&L, talk to an operator.